Docoh
Loading...

PHAS PhaseBio Pharmaceuticals

News

From Benzinga Pro
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
21 Dec 21
Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is
PhaseBio Pharma Highlights Publication Of Interim Results From Pivotal REVERSE-IT Phase 3 Trial Of Bentracimab In New England Journal Of Medicine Evidence
1 Dec 21
Biotech, News, FDA, General
Results previously presented in a Late-Breaking Science Session at the American Heart Association’s 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and
12 Health Care Stocks Moving In Monday's After-Market Session
29 Nov 21
Movers
Gainers
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Nov 21
Movers
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 7.36% to $35.0 during Wednesday's after-market session. The company's market cap stands at $690.0 million. As per the news, the Q3 earnings report came out 2 days ago.
70 Biggest Movers From Yesterday
16 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
PhaseBio Says Antiplatelet Candidate Achieved Primary Reversal Endpoint In Late-Stage Study
15 Nov 21
Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
PhaseBio Announces Interim Results From Pivotal REVERSE-IT Phase 3 Trial Of Bentracimab For Reversal Of Antiplatelet Effects Of Ticagrelor In Patients Requiring Urgent Surgery Or Experiencing Uncontrolled Major Or Life-Threatening Bleeding
15 Nov 21
News, FDA
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
PhaseBio Pharmaceuticals Q3 EPS $(0.66) Up From $(0.86) YoY, Sales $335.00K
10 Nov 21
Earnings, News
PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.66) per share. This is a 23.26 percent increase over losses of $(0.86) per share from the same period last year. The company reported $335.00
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
3 Nov 21
Biotech, News, Penny Stocks, Health Care, General
PhaseBio Announces Topline Results From Phase 2b Trial For Bentracimab; Co. Reports 'Trial achieved primary reversal endpoint in healthy, older volunteers'
3 Nov 21
Biotech, News, FDA, General
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced topline data from

Press releases

From Benzinga Pro
PhaseBio Provides Pemziviptadil (PB1046) Program Update
21 Dec 21
Press Releases
Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) voluntarily ended early by the Company in order to evaluate existing program data and determine next steps forward Company to reprioritize
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
1 Dec 21
Press Releases
Results previously presented in a Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and co-primary
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
18 Nov 21
Press Releases
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
15 Nov 21
Press Releases
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
10 Nov 21
Press Releases
Announced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
10 Nov 21
Press Releases
Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers